Login
Design Therapeutics, Inc. logo

Design Therapeutics, Inc.

designtx.com

What Do They Do?

Develops small-molecule treatments for people with inherited diseases caused by repeated genetic sequences, including Friedreich ataxia, Fuchs endothelial corneal dystrophy and myotonic dystrophy.

How Are They Changing?

Since the FY2025 annual report
Latest quarter: Q3 FY2026, the three months to Sep 30, 2026
Net income
▼ −19% (Loss)
vs −$17M in Q3 FY2025

Who Do They Compete With?

Competes with Larimar Therapeutics, Lexeo Therapeutics, Minoryx Therapeutics, PTC Therapeutics, Solid Biosciences, Capsida Biotherapeutics, Papillon Therapeutics, Voyager Therapeutics, Aurion Biotech, Emmecell, Kowa Pharmaceutical, Santen Pharmaceutical, Trefoil Therapeutics, AMO Pharma, Arrowhead Pharmaceuticals, Arthex Biotech, Avidity Biosciences, Dyne Therapeutics, EditForce, and Harmony Biosciences

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support